Skip to content

Study · Observational study · 2005

3 results

Beneficial effect of cerebrolysin on moderate and severe head injury patients: result of a cohort study.

Wong GK, Zhu XL, Poon WS

Acta neurochirurgica. Supplement1 Jan 2005Cited by 32 (Europe PMC)

PMID16463821 (opens in a new tab)DOI10.1007/3-211-32318-x_13 (opens in a new tab)PepBankPUB-16463821
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In moderate and severe head injury patients, 67% of the Cerebrolysin group attained good outcome (GOS 3-5) at 6 months.

    In plain wordsIn head injury patients, 67% of the Cerebrolysin group had a good outcome at 6 months.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableGood outcome at 6 months
    Study

    n: not reported in source

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    Good outcome
    67%
    Cerebrolysin group
    GOS scores defining good outcome
    3 to 5 GOS score
    Cerebrolysin group, good outcome at 6 months

    Source sentences

    Summary
    At 6 months, 67% of the patients (Cerebrolysin group) attained good outcome (GOS 3-5).
    2 context sentences
    Summary · context
    Aim of this study was to investigate whether addition of Cerebrolysin to the initial treatment regimen of moderate and severe head injury patients would improve their outcome.
    Summary · context
    The study group was compared with the historical cohort of patients from the hospital trauma data bank, with age, sex and admitting GCS matching.
  2. 02HumanObservational studyEfficacy outcome

    In head injury patients, Cerebrolysin showed a nonsignificant trend toward more good outcomes than the matched historical cohort.

    In plain wordsIn head injury patients, Cerebrolysin showed a nonsignificant trend toward better outcomes than the historical comparison group.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeGood outcome versus historical cohort
    Study

    n: not reported in source

    Comparator
    matched historical cohort
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    P value
    0.065
    good outcome comparison

    Source sentences

    Summary
    More patients tended to a good outcome in the Cerebrolysin group (P = 0.065).
    2 context sentences
    Summary · context
    Aim of this study was to investigate whether addition of Cerebrolysin to the initial treatment regimen of moderate and severe head injury patients would improve their outcome.
    Summary · context
    The study group was compared with the historical cohort of patients from the hospital trauma data bank, with age, sex and admitting GCS matching.
  3. 03HumanObservational studySafety outcome

    In head injury patients, no significant side effect required cessation of Cerebrolysin.

    In plain wordsIn head injury patients, no significant side effect required stopping Cerebrolysin.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableSide effects requiring cessation
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No significant side-effect requiring cessation of Cerebrolysin was noted.
    2 context sentences
    Summary · context
    Aim of this study was to investigate whether addition of Cerebrolysin to the initial treatment regimen of moderate and severe head injury patients would improve their outcome.
    Summary · context
    The study group was compared with the historical cohort of patients from the hospital trauma data bank, with age, sex and admitting GCS matching.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.